Hot Stocks Among Investors: Lumber Liquidators Holdings, Inc. (LL), ZIOPHARM Oncology, Inc. (ZIOP)

Shares of Lumber Liquidators Holdings, Inc. (NYSE:LL) opened at $28.9, and ended -3.28% lower at $28.05. Nearly 0.89 million shares were traded by the close, lower than its average daily volume of 1.16 million shares.

Lumber Liquidators Holdings, Inc. (LL) Analyst Opinion

Lumber Liquidators Holdings, Inc. has a consensus hold rating from 12 Wall Street analysts, and the number of shares currently sold short amount to at least 15.32% of shares outstanding. The stock sank -19.44% last month and is up 78.21 this year. Wall Street is only getting neutral on the stock, with 2 of analysts who cover LL having a buy-equivalent rating. Analysts have placed a $31.73 price target on Lumber Liquidators Holdings, Inc., suggesting a 13.12% gain from recent close. It’s currently trading about -32.13% below its 52-week high.

Lumber Liquidators Holdings, Inc. Earnings Surprise

Lumber Liquidators Holdings, Inc. (LL) failed to surprise the stock market in its last reported earnings when it earned $0.02 a piece versus the consensus-estimated $0.02. Its revenue totaled $261.66 million down -0.7% from the previous quarter.

Lumber Liquidators Holdings, Inc. (NYSE:LL) Intraday View

This stock (LL) is ahead of its 52-week low with 87.12%. Its last month’s stock price volatility remained 4.01% which for the week stands at 4.37%. The share price has moved backward from its 20 days moving average, trading at a distance of -14.42% and stays -21.21% away from its 50 days moving average. Over the last five days, shares have faced -8.72% losses and now is up 2.65% since hitting its 200-day moving average of $30.99. Lumber Liquidators Holdings, Inc. (LL) has made its way to a 12-month gain of 70.31%.

Turning to ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP), its shares were trading at $4.51 a gain of $0.21, on the trading floor. The stock, after opening at $4.23, touched a high of $4.57 before paring much of its gains. So far, analysts are sticking with their neutral recommendations with the consensus call at 2.5. ZIOPHARM Oncology, Inc. has 1 buy ratings, 4 holds and 0 sells even after the stock tumbled -42.77% from its high of $ 7.88 to a $677.45 million market value through last close.

ZIOPHARM Oncology, Inc. (ZIOP) Consensus Price Target

The company’s consensus rating on Reuter’s scale remained unchanged from 2.5 to 2.5 during a month. Analysts set a 12-month price target of $12.5 a share. The target implies a 177.16% spike from where the shares are currently trading. Also, the current price highlights a discount of 409.98% to analysts’ high consensus price target.

ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Intraday Trading

The counter witnessed a trading volume of 2.76 million shares versus an average volume of 1.33 million shares during last trading session. Its last month’s stock price volatility remained 7.64% which for the week approaches 6.32%. The lowest price the stock reached in the last trading day was $4.035 and compares with the $4.16 52-week low. The stock recovered 8.41% since its low point and has performed -15.7% year-to-date.

SHARE
Previous articleHot Stocks Report: NuStar GP Holdings, LLC (NSH), ITUS Corporation (ITUS)
Next articleAnalyst Recommendations And Earnings Forecast: Conatus Pharmaceuticals Inc. (CNAT), Denbury Resources Inc. (DNR)